Women who experienced depression during pregnancy were about four times as likely to experience PPD compared to women with no depression during pregnancy, with greater risk associated with depression during the first and third trimesters.
Postpartum SSRI treatment mitigated the negative associations between PPD and later maternal depression, partner relationship satisfaction, and child externalizing problems and ADHD symptoms up to 5 years after childbirth.
The largest GWAS study to date provides evidence that despite a high correlation with MDD, PPD may have unique genetic components.
Dexmedetomidine, an α2-adrenergic receptor agonist, shows promise in preventing postpartum depression, reducing symptoms and improving sleep and pain control in women with prenatal depression.
Vigilance is required in screening women who present with postpartum depression; a subset of women who screen positive for depression may actually have bipolar disorder.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
Machine learning can be used to analyze data contained within the electronic health record to accurately predict which individuals are at increased risk for postpartum depression.
A routinely administered single-item measure of sleep disturbance could identify pregnant individuals who are at risk for PPD and may benefit from depression prevention efforts.
Metabolic biomarkers in the cerebrospinal fluid may be used to identify women at high risk for postpartum depression.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
